PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?

Sylvie Lantuejoul¹, Nolwenn Le Stang², Francesca Damiola³, Arnaud Scherpereel⁴, Francoise Galateau-Sallé⁵

Affiliations

¹ Department of Biopathology, National referent center MESOPATH-National Clinicobiologic Databasis MESOBANK, Cancer Center of Léon Bérard, Lyon, France; UGA/INSERM U1209/CNRS 5309-Institute for Advanced Biosciences-University Grenoble Alpes, Grenoble, France. Electronic address: sylvie.lantuejoul@lyon.unicancer.fr.
² Department of Biopathology-Register MESONAT, Cancer Center of Léon Bérard, Lyon, France; INSERM UMR 1086, Cancers & Preventions, University Caen Basse-Normandie, Caen, France.
³ Department of Biopathology, National referent center MESOPATH-National Clinicobiologic Databasis MESOBANK, Cancer Center of Léon Bérard, Lyon, France.
⁴ University Lille, CHU Lille, MESOCLIN, Lille, France.
⁵ Department of Biopathology, National referent center MESOPATH-Base National Clinicobiologic Databasis MESOBANK Register multicenter MESONAT-Sante public cancer center of Léon Bérard, Lyon, France.

PMID: 28434510
DOI: 10.1016/j.jtho.2017.03.018

Free article

Editorial

PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?

Sylvie Lantuejoul et al. J Thorac Oncol. 2017 May.

Free article

. 2017 May;12(5):778-781.

doi: 10.1016/j.jtho.2017.03.018.

Authors

Sylvie Lantuejoul¹, Nolwenn Le Stang², Francesca Damiola³, Arnaud Scherpereel⁴, Francoise Galateau-Sallé⁵

Affiliations

¹ Department of Biopathology, National referent center MESOPATH-National Clinicobiologic Databasis MESOBANK, Cancer Center of Léon Bérard, Lyon, France; UGA/INSERM U1209/CNRS 5309-Institute for Advanced Biosciences-University Grenoble Alpes, Grenoble, France. Electronic address: sylvie.lantuejoul@lyon.unicancer.fr.
² Department of Biopathology-Register MESONAT, Cancer Center of Léon Bérard, Lyon, France; INSERM UMR 1086, Cancers & Preventions, University Caen Basse-Normandie, Caen, France.
³ Department of Biopathology, National referent center MESOPATH-National Clinicobiologic Databasis MESOBANK, Cancer Center of Léon Bérard, Lyon, France.
⁴ University Lille, CHU Lille, MESOCLIN, Lille, France.
⁵ Department of Biopathology, National referent center MESOPATH-Base National Clinicobiologic Databasis MESOBANK Register multicenter MESONAT-Sante public cancer center of Léon Bérard, Lyon, France.

PMID: 28434510
DOI: 10.1016/j.jtho.2017.03.018

No abstract available

PubMed Disclaimer

Comment on

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
Thapa B, Salcedo A, Lin X, Walkiewicz M, Murone C, Ameratunga M, Asadi K, Deb S, Barnett SA, Knight S, Mitchell P, Watkins DN, Boutros PC, John T. Thapa B, et al. J Thorac Oncol. 2017 May;12(5):850-859. doi: 10.1016/j.jtho.2017.02.013. Epub 2017 Feb 28. J Thorac Oncol. 2017. PMID: 28257959

Cited by

Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D. Sobhani N, et al. Mol Biol Rep. 2019 Jun;46(3):2713-2720. doi: 10.1007/s11033-019-04715-9. Epub 2019 Mar 6. Mol Biol Rep. 2019. PMID: 30840203
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Galateau Salle F, Le Stang N, Nicholson AG, Pissaloux D, Churg A, Klebe S, Roggli VL, Tazelaar HD, Vignaud JM, Attanoos R, Beasley MB, Begueret H, Capron F, Chirieac L, Copin MC, Dacic S, Danel C, Foulet-Roge A, Gibbs A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Nabeshima K, Picquenot JM, Rouquette I, Sagan C, Sauter JL, Thivolet F, Travis WD, Tsao MS, Weynand B, Damiola F, Scherpereel A, Pairon JC, Lantuejoul S, Rusch V, Girard N. Galateau Salle F, et al. J Thorac Oncol. 2018 Aug;13(8):1189-1203. doi: 10.1016/j.jtho.2018.04.023. Epub 2018 Apr 30. J Thorac Oncol. 2018. PMID: 29723687 Free PMC article.
Consensus Guideline for the Management of Peritoneal Mesothelioma.
Brown LM, Wilkins SG, Bansal VV, Su DG, Gomez-Mayorga J, Turaga KK, Gunderson CG, Lee B, Nash GM, Hays JL, Raghav KP, Husain AL, Kluger MD, Zauderer MG, Kindler HL, Alexander HR; Peritoneal Surface Malignancies (PSM) Consortium Group. Brown LM, et al. Ann Surg Oncol. 2025 Jun 25. doi: 10.1245/s10434-025-17358-x. Online ahead of print. Ann Surg Oncol. 2025. PMID: 40560500 Review.
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
Watanabe T, Okuda K, Murase T, Moriyama S, Haneda H, Kawano O, Yokota K, Sakane T, Oda R, Inagaki H, Nakanishi R. Watanabe T, et al. Oncotarget. 2018 Apr 17;9(29):20769-20780. doi: 10.18632/oncotarget.25100. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755688 Free PMC article.
The phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes.
Torricelli F, Spada F, Bishop C, Todd K, Nonaka D, Petrov N, Barberio MT, Ramsay AG, Ellis R, Ciarrocchi A, Apollonio B, Billè A. Torricelli F, et al. J Transl Med. 2025 Feb 20;23(1):208. doi: 10.1186/s12967-025-06193-z. J Transl Med. 2025. PMID: 39980060 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?

Affiliations

PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?

Authors

Affiliations

Comment on

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials